TrialPDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Trial details
- Registry ID
- NCT01155362
- Phase
- Phase 2
CELU
Celularity Incorporated
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's DiseaseNCT01155362 | Celularity Incorporated | Phase 2 | Completed | 2012-02Actual |
| Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.NCT02264288 | Celularity Incorporated | Phase 2 | Terminated | 2018-02-27Actual |
Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.
Trial details
- Registry ID
- NCT02264288
- Phase
- Phase 2
Latest recorded trial changes
PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
NCT01155362 · Celularity Incorporated
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: A reduction from baseline by 25% and/or > 100 points in the Crohn's Disease Activity Index (CDAI) scores at both Week 4 (Day 29) and at Week 6 (Day 43).
+ Updated value
measure: Percentage of Subjects With Clinical Response Based on Crohn's Disease Activity Index (CDAI) at Both Week 4 and Week 6
The saved outcome text may be shortened. Check the source for full wording.
Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.
NCT02264288 · Celularity Incorporated
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Complete wound closure of the index ulcer; measure: Safety (adverse events [type, frequency, and severity of AEs, and relationship of AEs to study drug], laboratory abnormalities, and hospitalizations
+ Updated value
measure: Percentage of Subjects With Complete Wound Closure of the Index Ulcer Within 3 Months
The saved outcome text may be shortened. Check the source for full wording.
Primary completion date
Recorded edit− Previous value
2018-02-28
+ Updated value
2018-02-27